Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Krishna Patel

Physician Assistant Raleigh, NC Physician Assistant

NPI 1902457518 CMS profile 10661602

7510 Ramble Way Ste 107, Raleigh, NC 27616

Open in the dashboard

General payments

$3,068

200 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krishna Patel of Raleigh, NC is reported in the CMS Open Payments database as having received $3,068 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $117 7
2024 General $576 34
2023 General $740 44
2022 General $611 39
2021 General $1,024 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krishna Patel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Krishna Patel were reported at $117. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Krishna Patel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,024 $132 $37–$438 $132
2022 $611 $155 $48–$522 $149
2023 $740 $167 $52–$557 $160
2024 $576 $178 $55–$600 $164
2025 $117 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $551 37 payments
  2. Pfizer Inc. $472 31 payments
  3. AbbVie, Inc. $376 28 payments
  4. Sanofi-Aventis U.S. LLC $292 15 payments
  5. Lilly USA, LLC $232 13 payments
  6. Amgen Inc. $142 14 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $103 6 payments
  8. AstraZeneca Pharmaceuticals LP $91 7 payments
  9. GlaxoSmithKline, LLC. $85 5 payments
  10. Esperion Therapeutics, Inc. $71 5 payments
  11. Other $653 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,068 200 payments
Products named General payments · program years 2021–2025
  1. Ozempic $367 24 payments
  2. RYBELSUS $367 24 payments
  3. NURTEC ODT $323 22 payments
  4. PAXLOVID $214 15 payments
  5. MOUNJARO $192 10 payments
  6. COMIRNATY $175 10 payments
  7. SOLIQUA 100/33 $169 9 payments
  8. ZAVZPRET $147 9 payments
  9. Wegovy $144 10 payments
  10. ELIQUIS $140 11 payments
  11. Other $2,563 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

636

Median for Physician Assistant: 241

Drug cost

$75,202

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 30 $44,615
Mounjaro Tirzepatide Brand 13 $16,828
Jardiance Empagliflozin Brand 12 $7,641
Metformin Hcl Er Metformin Hcl Brand 23 $797
Atorvastatin Calcium Generic 49 $580
Albuterol Sulfate Hfa Albuterol Sulfate Brand 14 $495
Levothyroxine Sodium Generic 46 $414
Rosuvastatin Calcium Generic 26 $395
Omeprazole Generic 15 $393
Lisinopril Generic 46 $342

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $61
$61 — —
MOUNJARO
  • Lilly USA, LLC $59
$59 13 —
Wegovy
  • Novo Nordisk Inc $46
$46 — —
ZAVZPRET
  • PFIZER INC. $40
$40 — —
VRAYLAR
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record